Sensei Biotherapeutics Files 8-K on Financials
Ticker: SNSE · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Sensei Biotherapeutics dropped its 8-K with financial results on 3/30/26.
AI Summary
Sensei Biotherapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits, with the primary document being an iXBRL 8-K.
Why It Matters
This filing provides investors with crucial updates on Sensei Biotherapeutics' financial performance and condition as of March 30, 2026.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate news of significant events.
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Filer of the 8-K
- March 30, 2026 (date) — Period of Report and Filing Date
FAQ
What specific financial information is being reported in this 8-K filing?
The filing is an 8-K reporting on Item 2.02: Results of Operations and Financial Condition, and Item 9.01: Financial Statements and Exhibits.
When was this 8-K filing accepted by the SEC?
The filing was accepted on March 30, 2026, at 07:35:21.
What is the CIK number for Sensei Biotherapeutics, Inc.?
The CIK number for Sensei Biotherapeutics, Inc. is 0001829802.
What is the business address of Sensei Biotherapeutics, Inc.?
The business address is 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850.
What SIC code is associated with Sensei Biotherapeutics, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2026-03-30 07:35:21
Filing Documents
- d118677d8k.htm (8-K) — 30KB
- d118677dex991.htm (EX-99.1) — 29KB
- 0001193125-26-130419.txt ( ) — 232KB
- snse-20260330.xsd (EX-101.SCH) — 3KB
- snse-20260330_def.xml (EX-101.DEF) — 16KB
- snse-20260330_lab.xml (EX-101.LAB) — 26KB
- snse-20260330_pre.xml (EX-101.PRE) — 16KB
- d118677d8k_htm.xml (XML) — 7KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release of Sensei Biotherapeutics, Inc., dated March 30, 2026 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: March 30, 2026 /s/ Christopher W. Gerry Christopher W. Gerry President and General Counsel 3